Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers. William also describes the evolution in medical affairs, why standards and certification matter, and how AI and new media channels are reshaping how drug information reaches patients and prescribers.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Welcome And Guest Background
- 1:15Liquor Store Lessons On People
- 7:37Why Medical Affairs Needs Standards
- 16:26Investing With An Operator’s Lens
- 20:45The Future Of Obesity Treatment
- 22:13When Commercialization Should Begin
- 27:39Modality Differences And Rare Disease Realities
- 31:45Regulatory And Commercial Must Sync
- 33:55Three Common Launch Mistakes
- 38:15Building Real-World Evidence Early
- 40:36Medical Affairs Expands And Meets AI
- 44:52Omnichannel Media And Misinformation
- 48:47DTC Ads: Benefits, Risks, And Oversight
- 51:28Where Doctors Get Information Now
- 53:08Final Advice Start Early Stay Agile